# Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

> **NCT02580747** · PHASE1 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Malignant Mesothelioma
- Pancreatic Cancer
- Ovarian Tumor
- Triple Negative Breast Cancer
- Endometrial Cancer
- Other Mesothelin Positive Tumors

## Interventions

- **BIOLOGICAL:** anti-meso-CAR vector transduced T cells

## Key facts

- **NCT ID:** NCT02580747
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2017-11
- **Final completion:** 2018-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580747, "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02580747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*